Two Contrarian Dividends With Triple-Digit Potential For Trump 2.0
1. Abbott Laboratories (ABT) surged 199% during Trump's first term. 2. ABT faces RFK Jr. concerns but has strong business fundamentals. 3. Continuous glucose monitoring is driving growth for Abbott's portfolio. 4. ABT's stock is currently undervalued, trading 15% below 2021 highs. 5. Preventative medicine trends could boost long-term demand for Abbott's products.